June 18 (Reuters) - EnteroMedics Inc's shares jumped about 37 percent in premarket trading on Wednesday, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the...
We are no longer providing equity research on EnteroMedics ETRM . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
EnteroMedics ETRM posted third-quarter results that ..... value estimate unchanged. Although EnteroMedics has begun to roll out its Maestro system ..... until after 2017. In the meantime, EnteroMedics burned through another $5.6 million
EntroMedics ETRM has made significant progress ..... valuation shortly. Now that EnteroMedics has shored up its cash ..... full year 2012. While EnteroMedics began its launch in Kuwait ..... 2013, especially after EnteroMedics has submitted its last
Now that EnteroMedics ETRM has made significant progress on ..... Australia. For the first time, EnteroMedics booked product revenue, following ..... distributor. Perhaps most important, EnteroMedics has put financing in place to keep
EnteroMedics ETRM saw its shares run up substantially ..... outcome has breathed some hope into EnteroMedics ' stock. However, this is not enough ..... to raise our fair value estimate for EnteroMedics at this time. Nonetheless, we are
EnteroMedics ETRM shared favorable data on its obesity ..... fourth quarter, which is when we expect EnteroMedics will run out of cash. We're not ..... what happened several years ago, when EnteroMedics reported impressive weight loss results
We're placing EnteroMedics ETRM under review as the company continues to burn through its available ..... holds steady, it should run out of funds in the fourth quarter. EnteroMedics is in a catch-22 situation: it must raise funds in order to
As EnteroMedics ETRM has shared more details on further ..... not be surprised if the agency asks EnteroMedics to conduct a new randomized controlled ..... pump another $4.8 million into EnteroMedics to fund further development of Maestro
very disappointing look at the preliminary data from EnteroMedics ' ETRM pivotal Empower trial in September, the company ..... makers. If it pursues another large-scale trial, EnteroMedics will again be seeking more cash.